presented by john byrd at 2014 asco annual meeting
DESCRIPTION
Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the Phase III RESONATETM Trial. Presented By John Byrd at 2014 ASCO Annual Meeting. Background. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Presented By John Byrd at 2014 ASCO Annual Meeting](https://reader033.vdocument.in/reader033/viewer/2022051402/568161cc550346895dd1b812/html5/thumbnails/1.jpg)
Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the Phase III <br />RESONATETM Trial
Presented By John Byrd at 2014 ASCO Annual Meeting
![Page 2: Presented By John Byrd at 2014 ASCO Annual Meeting](https://reader033.vdocument.in/reader033/viewer/2022051402/568161cc550346895dd1b812/html5/thumbnails/2.jpg)
Background
Presented By John Byrd at 2014 ASCO Annual Meeting
![Page 3: Presented By John Byrd at 2014 ASCO Annual Meeting](https://reader033.vdocument.in/reader033/viewer/2022051402/568161cc550346895dd1b812/html5/thumbnails/3.jpg)
RESONATE™ Phase 3 Study Design
Presented By John Byrd at 2014 ASCO Annual Meeting
![Page 4: Presented By John Byrd at 2014 ASCO Annual Meeting](https://reader033.vdocument.in/reader033/viewer/2022051402/568161cc550346895dd1b812/html5/thumbnails/4.jpg)
Study Objectives
Presented By John Byrd at 2014 ASCO Annual Meeting
![Page 5: Presented By John Byrd at 2014 ASCO Annual Meeting](https://reader033.vdocument.in/reader033/viewer/2022051402/568161cc550346895dd1b812/html5/thumbnails/5.jpg)
Inclusion Criteria
Presented By John Byrd at 2014 ASCO Annual Meeting
![Page 6: Presented By John Byrd at 2014 ASCO Annual Meeting](https://reader033.vdocument.in/reader033/viewer/2022051402/568161cc550346895dd1b812/html5/thumbnails/6.jpg)
Patient Disposition
Presented By John Byrd at 2014 ASCO Annual Meeting
![Page 7: Presented By John Byrd at 2014 ASCO Annual Meeting](https://reader033.vdocument.in/reader033/viewer/2022051402/568161cc550346895dd1b812/html5/thumbnails/7.jpg)
Baseline Characteristics
Presented By John Byrd at 2014 ASCO Annual Meeting
![Page 8: Presented By John Byrd at 2014 ASCO Annual Meeting](https://reader033.vdocument.in/reader033/viewer/2022051402/568161cc550346895dd1b812/html5/thumbnails/8.jpg)
Progression-Free Survival
Presented By John Byrd at 2014 ASCO Annual Meeting
![Page 9: Presented By John Byrd at 2014 ASCO Annual Meeting](https://reader033.vdocument.in/reader033/viewer/2022051402/568161cc550346895dd1b812/html5/thumbnails/9.jpg)
Progression-Free Survival by Baseline Characteristics and Molecular Features
Presented By John Byrd at 2014 ASCO Annual Meeting
![Page 10: Presented By John Byrd at 2014 ASCO Annual Meeting](https://reader033.vdocument.in/reader033/viewer/2022051402/568161cc550346895dd1b812/html5/thumbnails/10.jpg)
Overall Survival
Presented By John Byrd at 2014 ASCO Annual Meeting
![Page 11: Presented By John Byrd at 2014 ASCO Annual Meeting](https://reader033.vdocument.in/reader033/viewer/2022051402/568161cc550346895dd1b812/html5/thumbnails/11.jpg)
Overall Response to Therapy: <br />IRC and Investigator Assessment
Presented By John Byrd at 2014 ASCO Annual Meeting
![Page 12: Presented By John Byrd at 2014 ASCO Annual Meeting](https://reader033.vdocument.in/reader033/viewer/2022051402/568161cc550346895dd1b812/html5/thumbnails/12.jpg)
Best IRC Response without Second CT Confirmation
Presented By John Byrd at 2014 ASCO Annual Meeting
![Page 13: Presented By John Byrd at 2014 ASCO Annual Meeting](https://reader033.vdocument.in/reader033/viewer/2022051402/568161cc550346895dd1b812/html5/thumbnails/13.jpg)
Safety: Adverse Events (≥15%) Regardless of Attributiona
Presented By John Byrd at 2014 ASCO Annual Meeting
![Page 14: Presented By John Byrd at 2014 ASCO Annual Meeting](https://reader033.vdocument.in/reader033/viewer/2022051402/568161cc550346895dd1b812/html5/thumbnails/14.jpg)
Safety Overview
Presented By John Byrd at 2014 ASCO Annual Meeting
![Page 15: Presented By John Byrd at 2014 ASCO Annual Meeting](https://reader033.vdocument.in/reader033/viewer/2022051402/568161cc550346895dd1b812/html5/thumbnails/15.jpg)
Safety: Atrial Fibrillation and Bleeding-Related Adverse Events
Presented By John Byrd at 2014 ASCO Annual Meeting
![Page 16: Presented By John Byrd at 2014 ASCO Annual Meeting](https://reader033.vdocument.in/reader033/viewer/2022051402/568161cc550346895dd1b812/html5/thumbnails/16.jpg)
Conclusions
Presented By John Byrd at 2014 ASCO Annual Meeting
![Page 17: Presented By John Byrd at 2014 ASCO Annual Meeting](https://reader033.vdocument.in/reader033/viewer/2022051402/568161cc550346895dd1b812/html5/thumbnails/17.jpg)
Acknowledgments
Presented By John Byrd at 2014 ASCO Annual Meeting
![Page 18: Presented By John Byrd at 2014 ASCO Annual Meeting](https://reader033.vdocument.in/reader033/viewer/2022051402/568161cc550346895dd1b812/html5/thumbnails/18.jpg)
Acknowledgments
Presented By John Byrd at 2014 ASCO Annual Meeting